Industry
Medical - Diagnostics & Research
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Loading...
Open
529.40
Mkt cap
196B
Volume
3.3M
High
529.40
P/E Ratio
32.19
52-wk high
627.88
Low
511.71
Div yield
0.00
52-wk low
464.17
Portfolio Pulse from
November 19, 2024 | 5:30 pm
Portfolio Pulse from
November 14, 2024 | 10:30 am
Portfolio Pulse from
November 07, 2024 | 10:15 pm
Portfolio Pulse from Benzinga Insights
October 28, 2024 | 6:15 pm
Portfolio Pulse from Benzinga Newsdesk
October 24, 2024 | 6:24 pm
Portfolio Pulse from Benzinga Newsdesk
October 24, 2024 | 5:47 pm
Portfolio Pulse from Benzinga Newsdesk
October 24, 2024 | 5:40 pm
Portfolio Pulse from Benzinga Newsdesk
October 24, 2024 | 4:15 pm
Portfolio Pulse from Benzinga Newsdesk
October 24, 2024 | 3:23 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.